Cargando…

Determination of a clinically effective evobrutinib dose: Exposure–response analyses of a phase II relapsing multiple sclerosis study

The pharmacometric analysis of the double‐blind, randomized, phase II study (NCT02975349) investigating the safety and efficacy of evobrutinib, explored exposure–response relationships and suitable dosing regimens of evobrutinib for relapsing multiple sclerosis. Population pharmacokinetic (PK)/pharm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papasouliotis, Orestis, Mitchell, David, Girard, Pascal, Dangond, Fernando, Dyroff, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747124/ https://www.ncbi.nlm.nih.gov/pubmed/36126241 http://dx.doi.org/10.1111/cts.13407

Ejemplares similares

Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
por: Papasouliotis, Orestis, et al.
Publicado: (2022)

Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants
por: Scheible, Holger, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor
por: Bar-Or, Amit, et al.
Publicado: (2023)

Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations
por: Xiong, Wenyuan, et al.
Publicado: (2022)

Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis
por: Montalban, Xavier, et al.
Publicado: (2023)

Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Trial
por: Wallace, Daniel J., et al.
Publicado: (2022)

Human T-bet(+) B cell development is associated with BTK activity and suppressed by evobrutinib
por: Rijvers, Liza, et al.
Publicado: (2022)

Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study
por: Xiong, Wenyuan, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers
por: Becker, Andreas, et al.
Publicado: (2019)

Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis
por: Terranova, Nadia, et al.
Publicado: (2018)

Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials
por: Pitsiu, Maria, et al.
Publicado: (2023)

IN VITRO ASSESSMENT OF THE BIOLOGIC ACTIVITY OF INTERFERON BETA FORMULATIONS USED FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS
por: Scagnolari, Carolina, et al.
Publicado: (2014)

Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
por: Hermann, Robert, et al.
Publicado: (2019)

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
por: Comi, Giancarlo, et al.
Publicado: (2018)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study
por: Rivera, Victor M, et al.
Publicado: (2013)

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1
por: Traboulsee, Anthony, et al.
Publicado: (2018)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
por: Giovannoni, Gavin, et al.
Publicado: (2018)

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
por: De Stefano, Nicola, et al.
Publicado: (2021)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data
por: Kareva, Irina, et al.
Publicado: (2021)

Correction to: Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data
por: Kareva, Irina, et al.
Publicado: (2021)

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS
por: Freedman, Mark S., et al.
Publicado: (2019)

Correction: oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
Publicado: (2019)

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
por: Hu, Xiao, et al.
Publicado: (2017)

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
por: Gibiansky, Ekaterina, et al.
Publicado: (2020)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma
por: Ferron‐Brady, Geraldine, et al.
Publicado: (2021)

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models
por: Pantoja, Kristyn, et al.
Publicado: (2022)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Kinetics of free and ligand-bound atacicept in human serum
por: Eslami, Mahya, et al.
Publicado: (2022)

Phase II study of ‘high-dose’ celecoxib and metronomic ‘low-dose’ cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma
por: Abdel-Bary, N, et al.
Publicado: (2009)

Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
por: Xiong, Wenyuan, et al.
Publicado: (2021)

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study
por: Montalban, Xavier, et al.
Publicado: (2018)

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2021)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
por: Miller, Aaron E, et al.
Publicado: (2012)

Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis
por: Paul, Friedemann, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_7t8u2scg192l7qn14kvqkqeugu